A prospective study showed that the medication did not reduce events, including non-fatal MI, non-fatal stroke, or cardiovascular death, in patients with IHD.
Treating severe hypertriglyceridaemia patients with subcutaneous pegozafermin significantly reduced triglycerides across all study dose groups.
SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisation for heart failure across HFpEF/HFmrEF patient subgroups.
In severe ischaemic left ventricular systolic dysfunction patients, PCI did not reduce the composite incidence of all cause death or hospitalisation for heart failure.
The BOX trial shows that outcomes of comatose patients after an OHCA are not affected by shifting targets of oxygenation or blood-pressure.
A high-dose vaccination (60 μg of haemagglutinin antigen) in older adults reduced death risk by 49% and hospitalisation by 64%, compared with standard-dose vaccination.
PPIs should work against gastrointestinal complaints, but some patients need them permanently. Researchers have set therapy guidelines for this.
Adding acetazolamide to loop diuretics in ADHF patients with volume overload improved rates of successful decongestion within 3 days.
Results point to a screening target age below 70 years, for a substantial reduction of combined endpoints of death, stroke, or myocardial infarction.
The TIME trial reported that taking antihypertensives mornings or evenings, provides identical protection against heart attack, stroke, or vascular death.
After blinded review of initial LVEF assessment, cardiologists were less likely to substantially change final reports with initial AI than sonographer assessment.
The 'polypill' dose of aspirin, ramipril, and atorvastatin prevents secondary CV events in people ≥65 years old who previously had myocardial infarction.
Focused ultrasound waves can be used to destroy tissue with millimetre precision. The innovative technology is being tested in the 'HOPE4LIVER' study.
Dapagliflozin reduced cardiovascular death risk or worsening heart failure in patients with mildly reduced and preserved ejection fraction.
Trial results show no evidence that neprilysin inhibition raised cognitive impairment risk due to brain amyloid-β accumulation, for HFmrEF/HFpEF patients.
mRNA vaccines should induce viral proteins directly in the body and stimulate the immune system to produce broadly neutralising antibodies against HIV.
Vaccine prospects were revolutionised thanks to new mRNA vaccines against COVID-19. Can this knowledge transfer for the HIV vaccine quest?
ARTs for HIV treatment are highly effective, but rebounds occurs after medicine discontinuation. This article looks at developing treatment options in this field.
In Uganda, AIDS-related mortality has dropped rapidly. Quick HIV tests and more screening options are just some of the measures helping the developing country.
Modern HIV therapies cannot yet remove the viruses from the body. Treatments that attack viral reservoirs are of great hope to eliminate HIV in a patient.